The price of Viking Therapeutics Inc (NASDAQ:VKTX) shares last traded on Wall Street fell -1.28% to $28.58.
VKTX stock price is now 8.56% away from the 50-day moving average and -32.25% away from the 200-day moving average. The market capitalization of the company currently stands at $3.21B.
With the price target of $104, Cantor Fitzgerald recently initiated with Overweight rating for Viking Therapeutics Inc (NASDAQ: VKTX). On April 08, 2025, Goldman recently initiated its ‘Neutral’ rating on the stock quoting a target price of $30, while ‘Scotiabank’ rates the stock as ‘Sector Outperform’
In other news, Rouan Sarah Kathryn, Director bought 1,240 shares of the company’s stock on Mar 31 ’25. The stock was bought for $29,943 at an average price of $24.15. Upon completion of the transaction, the Director now directly owns 1,240 shares in the company, valued at $35439.2. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 06 ’25, President & CEO Lian Brian sold 194,490 shares of the business’s stock. A total of $8,313,601 was realized by selling the stock at an average price of $42.75. This leaves the insider owning 2,366,570 shares of the company worth $67.64 million. A total of 2.96% of the company’s stock is owned by insiders.
During the past 12 months, Viking Therapeutics Inc has had a low of $18.92 and a high of $81.73. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 44.25, and a quick ratio of 44.25.
